Developing and commercializing specialized therapies for the treatment of rare diseases by using the patient’s own blood
Latest NewsView all
EryDel Announces Top-line Results from Phase 3 ATTeST Trial Demonstrating Significant ...
July 12, 2021Read more
Taking part in the First International Campaign Raising Awareness for Ataxia ...
December 04, 2020Read more
EryDel’s proprietary platform technology is an easy to use, fast and automatic bedside procedure, to encapsulate small and large molecules including therapeutic enzymes in patients’ red blood cells. The cells are immediately re-infused into patients providing prolonged half-life in circulation, reduced immunogenicity, better tolerability and predictable vascular distribution.Discover